	September 30, 2020		December 31, 2019
Equity investments at fair value	$	2,207	$	4,183
Equity investments under measurement alternative		14,738		14,954
Debt securities classified under available-for-sale method		5,765		5,047
Total other investments	$	22,710	$	24,184

Unrealized gains and losses recognized in other expense (income) during the three and nine months ended September 30, 2020 on equity investments still held at September 30, 2020 are losses of $506 and $1,272 (2019 – loss of $274 and gain of $264). There were no impairments or adjustments to equity investments under the measurement alternative for the three and nine months ended September 30, 2020 and September 30, 2019.

The Company’s debt securities accounted for under the available-for-sale method consist of convertible debt instruments with contractual maturities in 2022. Total unrealized loss of $148 in accumulated other comprehensive income at September 30, 2020 (December 31, 2019 - $302) relates to the long-term available-for-sale debt securities. The Company’s allowance for credit losses on debt securities classified as available-for-sale is $0 at September 30, 2020 (December 31, 2019 – $0) and no related credit loss expenses were recorded during the three and nine months ended September 30, 2020 (2019 – $0 and $0).

Equity method investments are comprised of the Company’s joint venture with Anheuser-Busch InBev (“AB InBev”) in Plain Vanilla Research Limited Partnership (“Fluent”) and the Company’s joint venture with Cannfections Group Inc. (“Cannfections”). As of September 30, 2020, there are no changes to the status of the Company’s assessment of its joint ventures.

During the nine months ended September 30, 2020, the Company contributed $2,323 to Fluent (2019 - $10,090). The Company provides production support services to Fluent on a cost recovery basis. For the nine months ended September 30, 2020, total fees charged were $3,109 (2019 - $0). Total amounts included in accounts payable is $441 at September 30, 2020 (December 31, 2019 – accounts receivable of $388). At September 30, 2020, the maximum exposure to loss is limited to the Company’s equity investment in Fluent.

During the nine months ended September 30, 2020, the Company made no capital contributions to Cannfections (2019 - $3,600). At September 30, 2020, the maximum exposure to loss is limited to the Company’s equity investment in Cannfections.

The Company’s ownership interests in its equity method investments as of September 30, 2020 and December 31, 2019 and (loss) gain from equity method investments for the nine months ended September 30, 2020 were as follows:

	Approximate	Carrying value		(Loss) gain from equity method investments for the nine months ended
	ownership %	September 30, 2020		September 30, 2020
Investment in Fluent	50%	$	5,147	$	(4,725	)
Investment in Cannfections	50%		3,764		230
Total equity method investments		$	8,911	$	(4,495	)

	Approximate	Carrying value		(Loss) gain from equity method investments for the nine months ended
	ownership %	December 31, 2019		September 30, 2019
Investment in Fluent	50%	$	7,836	$	(1,837	)
Investment in Cannfections	50%		3,612		—
Total equity method investments		$	11,448	$	(1,837	)

Summary financial information for the Company’s equity method investments on an aggregate basis is as follows:

	September 30, 2020		December 31, 2019
Current assets	$	12,346	$	13,942
Noncurrent assets	$	5,205	$	4,987
Current liabilities	$	4,965	$	1,561
Noncurrent liabilities	$	—	$	—

	Nine months ended September 30,
	2020			2019
Revenue	$	4,854		$	—
Gross profit	$	2,032		$	—
Net loss	$	(8,991	)	$	(3,160	)